Skip to search formSkip to main contentSkip to account menu

DORA-22

Known as: ((2R,5R)-5-((5-fluoropyridin-2-yl)oxymethyl)-2-methylpiperidin-1-yl)-(5-fluoro-2-pyrimidin-2-ylphenyl)methanone 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Insomnia-related sleep disruption can contribute to impaired learning and memory. Treatment of insomnia should ideally improve… 
2017
2017
Emotionally salient situations usually trigger arousal along with autonomic and neuroendocrine reactions. To determine whether… 
2017
2017
Chronic insomnia is defined as a persistent difficulty with sleep initiation maintenance or non‐restorative sleep. The… 
2016
2016
STUDY OBJECTIVES In addition to enhancing sleep onset and maintenance, a desirable insomnia therapeutic agent would preserve… 
2014
2014
BackgroundThe current standard of care for insomnia includes gamma-aminobutyric acid receptor A (GABAA) activators, which promote… 
2014
2014
The ability to awaken from sleep in response to important stimuli is a critical feature of normal sleep, as is maintaining sleep… 
Highly Cited
2013
Highly Cited
2013
BackgroundDrugs targeting insomnia ideally promote sleep throughout the night, maintain normal sleep architecture, and are devoid… 
Highly Cited
2013
Highly Cited
2013
Selective orexin receptor antagonism promotes sleep at doses lower than those that impair attention and memory in contrast to the… 
2013
2013
Dual orexin receptor antagonists (DORAs) induce sleep by blocking orexin 1 and orexin 2 receptor-mediated activities responsible… 
Highly Cited
2012